Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current. 

Category
done
done
done
Displaying 1 - 22 of 22
Date Sort ascending
CL_2022-22.pdf

INFORMATION ONLY
Results of RFP for Plasma Derived PPRP

Customer Letter 2022-22 (PDF)

CL_2022-21.pdf

ACTION REQUIRED
Introducing New Formats of HyperHep B®

Customer Letter 2022-21 (PDF) | HyperHEP B® - Product Update (PDF)

CL_2022-20.pdf

INFORMATION ONLY
Kamada acquiring Hyperimmune Products from Saol

Customer Letter 2022-20 (PDF) | Kamada Customer Letter (PDF)

CL_2022-19.pdf

INFORMATION ONLY
Ink Issues on Fresh Blood Component Labels

Customer Letter 2022-19 (PDF)

CL_2022-18.pdf

ACTION REQUIRED
Plans for National Deployment of Pathogen Reduced Platelets and Plasma

Customer Letter 2022-18 (PDF)

CL_2022-17.pdf

INFORMATION ONLY
Eloctate 2000IU Supply Update

Customer Letter 2022-17 (PDF)

CL_2022-16.pdf

ACTION REQUIRED
Label and Product Code Changes for Rare International Red Blood Cells

Customer Letter 2022-16 (PDF)

CL_2022-15.pdf

INFORMATION ONLY
New Administrator for ProCare Patient Support Program

Customer Letter 2022-15 (PDF) | Procare Patient Advisory Letter (PDF)Procare HCP Advisory Letter (PDF)

CL_2022-14.pdf

INFORMATION ONLY
Donor High Titre Isohemagglutinin (Anti-A /Anti-B) Testing

Customer Letter 2022-14 (PDF)

CL_2022-13.pdf

INFORMATION ONLY
Partnering to Improve Red Blood Cell Utilization

Customer Letter 2022-13 (PDF)

CL_2022-12.pdf

INFORMATION ONLY
Adynovate® Ancillary Item Changes

Customer Letter 2022-12 (PDF) | ADYNOVATE® changes and timelines(PDF)

CL_2022-11.pdf

ACTION REQUIRED
Changes to the Hospital Customer Feedback Process

Customer Letter 2022-11 (PDF)

CL_2022-10.pdf

INFORMATION ONLY
2021 Recombinant Request for Proposals - Zonovate® and Esperoct® Availability & Updates to the Request for Patient Designated Plasma Protein & Related Products Form

Customer Letter 2022-10 (PDF) | Esperoct Welcome Letter (PDF) | Zonovate Welcome Letter (PDF) | Zonovate Product Profile (PDF) | Esperoct Product Profile (PDF)F801219 Sample (PDF)

CL_2022-09.pdf

INFORMATION ONLY
Discontinuation of Apheresis Fresh Frozen Plasma 500mL

Customer Letter 2022-09 (PDF)

CL_2022-08.pdf

INFORMATION ONLY
J82 Biodegradable Insulator Switchover

Customer Letter 2022-08 (PDF)

CL_2022-07.pdf

INFORMATION ONLY
Recommendations for Recipient Notification for Blood Component Recalls Related to COVID-19

Customer Letter 2022-07 (PDF) | National Recipient Advisory Committee Recommendation (PDF)

CL_2022-06.pdf

INFORMATION ONLY
FAQ for the Request for Proposals (RFP) for Recombinant Plasma Protein and Related Products (PPRP)

Customer Letter 2022-06 (PDF) | 2021 Recombinant RFP FAQ: Process, Results, and Product Availability (PDF)

CL_2022-05.pdf

INFORMATION ONLY
Introduction of Cuvitru® 10g/50mL

Customer Letter 2022-05 (PDF) | Takeda - Introducing a new format of CUVITRU® 10 g/50ml in Canada (PDF)

CL_2022-04.pdf

INFORMATION ONLY
Implementation Update: Introduction of Psoralen Treated Pooled Platelets in Ottawa (to be distributed to hospitals NOT served by Ottawa Site)

Customer Letter 2022-04 (PDF)

CL_2022-03.pdf

INFORMATION ONLY
Health Canada approved - Anticoagulant labelling changes for Apheresis products

Customer Letter 2022-03 (PDF)

CL_2022-02.pdf

INFORMATION ONLY
Cutaquig® Shelf Life Extension

Customer Letter 2022-02 (PDF) | Cutaquig Extended Shelf Life - Customer Letter (PDF)

CL_2022-01.pdf

INFORMATION ONLY
Implementation Update: Introduction of Psoralen Treated Pooled Platelets (to be distributed to hospitals served by Ottawa Site ONLY)

Customer Letter 2022-01 (PDF)